Author(s):
Arun Kumar T, Anitha K
Email(s):
arunkumar7x@gmail.com
DOI:
10.52711/0974-360X.2026.00653 
Address:
Arun Kumar T1*, Anitha K2
1M. Pharm Graduate, Department of Pharmaceutical Chemistry, Madras Medical College, Chennai, Tamil Nadu – 600003, India.
2Assistant Professor, Department of Pharmaceutical Chemistry, Dr MGR Educational and Research Institute, Chennai – 600077, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 10,
Year - 2026
ABSTRACT:
Lung cancer is one of the most prevalent and lethal malignancies globally, responsible for more than 1.3 million deaths each year. Cyclin-dependent kinase 2(CDK2) plays a crucial role in cell cycle regulation and has emerged as a promising therapeutic target in cancer drug development. This study focused on the design, synthesis, and evaluation of novel isatin-piperazine derivatives as potential antilung cancer agents targeting the CDK2 enzyme. A total of 110 ligands were designed using in silico drug design strategies and screened through molecular docking with AutoDock Tools 4.2 version 1.5.6. The compounds were evaluated for drug-likeness according to Lipinski's rule of five, along with ADMET properties and toxicity predictions using Molinspiration and Osiris Property Explorer. Among the designed molecules, five derivatives with high docking scores and synthetic feasibility were selected for synthesis. Structural characterization was conducted using IR, HNMR spectroscopic techniques. In vitro anticancer evaluation of the selected compounds TK1 and TK4 against the A549 lung cancer cell line, using the MTT assay, yielded IC values of 46.49µg/mL and 77.97µg/mL, respectively, demonstrating superior cytotoxic activity compared to the reference drug, artemisinin (IC 100µg/mL). These results indicate that is at in-based scaffolds show significant potential as CDK2 inhibitors and may serve as leads for the development of novel antilung cancer therapeutics.
Cite this article:
Arun Kumar T, Anitha K. Design, Synthesis, Characterization and In-vitro Evaluation of Novel Isatin derivatives as Anti-lung Cancer agents inhibiting CDK2 Enzyme. Research Journal Pharmacy and Technology. 2026;19(10):4691-6. doi: 10.52711/0974-360X.2026.00653
Cite(Electronic):
Arun Kumar T, Anitha K. Design, Synthesis, Characterization and In-vitro Evaluation of Novel Isatin derivatives as Anti-lung Cancer agents inhibiting CDK2 Enzyme. Research Journal Pharmacy and Technology. 2026;19(10):4691-6. doi: 10.52711/0974-360X.2026.00653 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-10-29
REFERENCE:
1. Hou H, Qu B, Su C, Hou G, Gao F. Design, synthesis and anti-lung cancer evaluation of 1, 2, 3-Triazole tethered dihydroartemisinin-isatin hybrids. Frontiers in Pharmacology. 2021; 12: 801580.
2. Krishnegowda G, Gowda AP, Tagaram HR, Staveley-O’Carroll KF, Irby RB, Sharma AK, Amin S. Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway. Bioorganic and medicinal chemistry. 2011; 19(20): 6006-14.
3. Havrylyuk D, Kovach N, Zimenkovsky B, Vasylenko O, Lesyk R. Synthesis and anticancer activity of isatin‐based pyrazolines and thiazolidines conjugates. Archiv der Pharmazie. 2011; 344(8): 514-22.
4. Chauhan G, Pathak DP, Ali F, Bhutani R, Kapoor G, Khasimbi S. Advances in synthesis, derivatization and bioactivity of isatin: a review. Current Organic Synthesis. 2021; 18(1): 37-74.
5. Ding Y, Zhao L, Fu Y, Hao L, Fu Y, Yuan Y, Yu P, Teng Y. Synthesis and antiproliferatory activities evaluation of multi-substituted isatin derivatives. Molecules. 2020; 26(1): 176. 6.
6. Firoozpour L, Gao L, Moghimi S, Pasalar P, Davoodi J, Wang MW, Rezaei Z, Dadgar A, Yahyavi H, Amanlou M, Foroumadi A. Efficient synthesis, biological evaluation, and docking study of isatin based derivatives as caspase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2020; 35(1): 1674-84.
7. Nain S, Mathur G, Anthwal T, Sharma S, Paliwal S. Synthesis, characterization, and antibacterial activity of new isatin derivatives. Pharmaceutical Chemistry Journal. 2023; 57(2): 196-203.
8. Bogdanov AV, Vazykhova AB, Khasiyatullina NR, Krivolapov DB, Dobrynin AB, Voloshina AD, Mironov VF. New N-Mannich bases obtained from isatin and piperazine derivatives: the synthesis and evaluation of antimicrobial activity. Chemistry of Heterocyclic Compounds. 2016; 52: 25-30.
9. Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, Minna JD. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. British journal of cancer. 1988; 57(6): 540-7.
10. Hamzehloueian M, Sarrafi Y, Darroudi M, Arani MA, Darestani RN, Safari F, Foroumadi A. Synthesis, antibacterial and anticancer activities evaluation of new 4-thiazolidinone indolin-2-one analogs. Biointerface Res Appl Chem. 2022; 12: 8094-104.
11. Sabt, A., Eldehna, W. M., Al-Warhi, T., Alotaibi, O. J., Elaasser, M. M., Suliman, H., and Abdel-Aziz, H. A. (2020, January 1). Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights. Journal of Enzyme Inhibition and Medicinal Chemistry. Informa UK Limited. http://doi.org/10.1080/14756366.2020.1806259
12. Mandour, A. A., Nassar, I. F., Abdel Aal, M. T., Shahin, M. A. E., El-Sayed, W. A., Hegazy, M., … Ismail, N. S. M. (2022, July 10). Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4- d ]pyrimidine and pyrazolo[4,3- e ][1,2,4]triazolo[1,5- c ]pyrimidine scaffold with apoptotic activity. Journal of Enzyme Inhibition and Medicinal Chemistry. Informa UK Limited. http://doi.org/10.1080/14756366.2022.2086866
13. Male, D., Fergus, K., and Yufe, S. (2022, March 25). ‘Weighing Losses and Gains: Evaluation of the Healthy Lifestyle Modification After Breast Cancer Pilot Program. Frontiers in Psychology. Frontiers Media SA. http://doi.org/10.3389/fpsyg.2022.814671
14. Hwang, P. L. (1991, November). Biological activities of oxygenated sterols: Physiological and pathological implications. BioEssays. Wiley. http://doi.org/10.1002/bies.950131108
15. Finnanger, T. G., Andersson, S., Chevignard, M., Johansen, G. O., Brandt, A. E., Hypher, R. E., … Stubberud, J. (2022, February 3). Assessment of Executive Function in Everyday Life—Psychometric Properties of the Norwegian Adaptation of the Childrens Cooking Task. Frontiers in Human Neuroscience. Frontiers Media SA. http://doi.org/10.3389/fnhum.2021.761755
16. Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati. Health-Related Quality of Life in Non-Small Cell Lung Cancer (NSCLC) Patients with Mutation of Epidermal Growth Factor Receptor (EGFR) in Indonesia. Research J. Pharm. and Tech. 2020; 13(1): 443-447.
17. Seftika Sari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati. Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives. Research Journal of Pharmacy and Technology. 2022; 15(4): 1598-2
18. Novita Andayani, Yunita Arliny, Syarifah Fera, Basti Handoko. Overview of The Neutrophil-Lymphocyte Ration (NLR) as a Prognosis Biomarker of Non-Small Cell Lung Cancer (NSCLC). Research Journal Pharmacy and Technology. 2024; 17(12): 5839-2.
19. Sasikumar.K, Tharabai.R , Sathya Devi. S, Abdul Hasan Sathali. A. Synthesis and Characterization of 1-Substituted Isatin Derivatives by Mannich Reaction. Research J. Pharm. and Tech. 2014; 7(12): 1429-1432
20. Y. B. Zambare, S. S. Chitlange, R. P. Bhole. Design and Screening of PPAR-γ agonist based Isatin derivatives and its remarkable activity as Anti-cancer and Anti-diabetic. Research J. Pharm. and Tech. 2019; 12(4): 2017-2026.